[{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Tetraphase Pharmaceuticals","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$55.0 million","newsHeadline":"Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melinta Therapeutics Nabs FDA Nod for More Convenient Rework of Antibiotic Orbactiv","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"New American Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL\u00ae (metoprolol succinate) From New American Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO\u2122 (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"$30.0 million","newsHeadline":"Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of Rezzayo\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$141.9 million","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO\u2122 (rezafungin for injection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Melinta Therapeutics
VNRX-5022 (cefepime) & taniborbactam combination is an investigational IV beta-lactam/beta-lactamase inhibitor antibiotic, being developed for treatment of complicated urinary tract infections, including pyelonephritis & bacterial pneumonia (HABP/VABP) in adults.
The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being used for the treatment and prevention of adult patients with candidemia and invasive candidiasis.
The partnership aims to advance two antibiotics currently FDA-approved for adults, Baxdela (delafloxacin) and Vabomere (meropenem and vaborbactam), for use in pediatrics and also for the development of Baxdela against biothreat pathogens for both adults and children.
Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products in Canada.
Under the agreement, Melinta acquired exclusive rights to commercialize Rezzayo (rezafungin) in the U.S. from Cidara. Cidara recently received FDA approval for REZZAYO™, a novel, once-weekly echinocandin antifungal approved for candidemia and invasive candidiasis.
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
CD101 (rezafungin) is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections.
Under the terms of the Agreement, Cidara will continue to lead the ongoing global Phase 3 ReSPECT prophylaxis study, as well as the regulatory activities for the approval of CD101 (rezafungin) in both the treatment and prophylaxis indications.
TOPROL-XL®, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic, heart failure of specific origins.